Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

Building on an early partnership with Allogene in blood cancers, Canadian start-up Notch has raised $85 million in a series A round designed to bring the first two off-the-shelf cell therapy programs from its wholly-owned pipeline toward the clinic.

Spun out of the Sunnybrook Research Institute and the University of Toronto, Notch Therapeutics Inc. is using gene-edited induced pluripotent stem cells (iPSCs) to develop allogeneic cell therapies...